|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Pulmonary Arterial Hypertension clinical community builds order from chaos
Datamonitor, March 2009, Pages: 134
Despite an explosion in the number of drugs and treatment strategies available, pulmonary arterial hypertension is still a rapidly fatal condition for a small, hard to identify patient group. A small clinical elite is currently leading the way in advancing treatment outcomes, and is central to determining which new treatment strategies are used.
Scope
- Defining the key clinical characteristics of the pulmonary arterial sector that present a unique commercial challenge
- Translation of critical clinical issues into pertinent practical considerations for both incumbent players and new market entrants
- Insight into the challenge of determining a patient potential in the context of a miniscule diagnosed population and a phenomenal 'at-risk' population
- Assessment of future directions in management and the changing roles of therapies
Highlights of this title
The estimated 8,11516,186 diagnosed pulmonary arterial hypertension patients across the US, Japan, France, Germany, Italy, Spain and the UK represent a fraction of the 28.0135.6 million group known to be at elevated risk. Identifying the true patient potential within known high risk groups remains highly problematic.
A small, but relatively powerful clinical community has brought structure, order and an increasing influence to bear on management through a few specialist centers. This internationally cohesive group has been responsible for laying the foundations for substantial volumes of data pertaining to patients managed in increasingly standardized ways.
A high number of approved and late stage pipeline products, and the increasing exploration of combination therapeutics places a higher emphasis than normal on the perceptions of specialist clinicians, who will increasingly need to triage their attentions to the most promising avenues for improving outcomes.
Key reasons to purchase this title
- Understand the challenges in aligning product positioning to the demands of the future clinical paradigm
- Identify development strategies that allow optimal buy-in from an increasingly important clinical community
- Qualify market expectations against the practical realities of targeting this fragmented, niche patient population
Customers who bought this item also bought
U.S. Pulmonary Arterial Hypertension Markets
Pulmonary Arterial Hypertension: Diagnosis and Evidence-Based Treatment
Stakeholder Perspectives: Pulmonary Arterial Hypertension - A Small Market Gets Big Attention
New Therapies for Pulmonary Arterial Hypertension: Orphan Drugs Seeking Opportunities in Wider Related Indications
Strategic Analysis of the Kenyan Hypertension Markets
Handbook of Hypertension
Renin Inhibitors: A Novel Approach to Hypertension
Pulmonary Hypertension: New Potential in a Limited Market
Chinese Markets for Hypertension Drugs
China Hypertension Drug Market 2008
Hypertension and Heart Failure - Evaluation and Management Clincial Guidelines
Hypertension: Treatments and Prescribing Practices - A Global Survey
|
|
|
|
